Literature DB >> 21380694

Detection of BCR-ABL in Hematological Malignancies by RT-PCR.

N C Cross1.   

Abstract

The presence of a novel, minute chromosome m the cells of patients with chrome myeloid leukemia (CML) was first described m 1960 by Nowell and Hungerford (1). The Philadelphia (Ph) chromosome, as it became known, was shown subsequently by banding techniques to result from a recrprocal translocanon between the long arms of chromosomes 9 and 22 t(9;22) (q34;qll) (2). Molecular studies demonstrated that the translocatton disrupted the normal ABL and BCR genes on chromosomes 9 and 22, respectively, grvmg rise to a chimeric BCR-ABL gene encoding a fusion protein with transforming ability (3). The reciprocal ABL-BCR product is also transcriptionally active in the majority of cases (4, 5).

Entities:  

Year:  1996        PMID: 21380694     DOI: 10.1385/0-89603-341-4:25

Source DB:  PubMed          Journal:  Methods Mol Med        ISSN: 1543-1894


  5 in total

1.  Successful Management of a Pregnant Patient With Chronic Myeloid Leukemia Receiving Standard Dose Imatinib.

Authors:  Stefania Stella; Elena Tirró; Michele Massimino; Silvia Rita Vitale; Sabina Russo; Maria Stella Pennisi; Adriana Puma; Chiara Romano; Sandra DI Gregorio; Vanessa Innao; Fabio Stagno; Francesco DI Raimondo; Caterina Musolino; Livia Manzella
Journal:  In Vivo       Date:  2019 Sep-Oct       Impact factor: 2.155

2.  Rapid decline of Philadelphia-positive metaphases after nilotinib treatment in a CML patient expressing a rare e14a3 BCR-ABL1 fusion transcript: A case report.

Authors:  Michele Massimino; Stefania Stella; Elena Tirrò; Maria Letizia Consoli; Maria Stella Pennisi; Adriana Puma; Silvia Rita Vitale; Chiara Romano; Valentina Zammit; Fabio Stagno; Francesco Di Raimondo; Livia Manzella
Journal:  Oncol Lett       Date:  2019-07-04       Impact factor: 2.967

3.  Optimal Response in a Patient With CML Expressing BCR-ABL1 E6A2 Fusion Transcript With Nilotinib Therapy: A Case Report.

Authors:  Livia Manzella; Elena Tirrò; Silvia Rita Vitale; Adriana Puma; Maria Letizia Consoli; Loredana Tambè; Maria Stella Pennisi; Sandra DI Gregorio; Chiara Romano; Cristina Tomarchio; Francesco DI Raimondo; Fabio Stagno
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

4.  Frequency of BCR-ABL Transcript Types in Syrian CML Patients.

Authors:  Sulaf Farhat-Maghribi; Wafa Habbal; Fawza Monem
Journal:  J Oncol       Date:  2016-05-30       Impact factor: 4.375

5.  CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy.

Authors:  Ross Kinstrie; Gillian A Horne; Heather Morrison; David Irvine; Chinmay Munje; Eduardo Gómez Castañeda; Hothri A Moka; Karen Dunn; Jennifer E Cassels; Narissa Parry; Cassie J Clarke; Mary T Scott; Richard E Clark; Tessa L Holyoake; Helen Wheadon; Mhairi Copland
Journal:  Leukemia       Date:  2020-01-02       Impact factor: 11.528

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.